MUC16 expression and risk of adenocarcinoma metastases to peritoneum, pleura, leptomeninges, and brain.
Approximately 5% to 15% of central nervous system metastases by solid tumors spread to the leptomeninges. Transmembrane MUC16 is thought to facilitate anchoring of metastases to other tissues particularly those expressing mesothelin such as pleura and peritoneum. Recently, we have demonstrated that mesothelin is also expressed in the leptomeninges. Mesothelin has a high affinity for MUC16 and mesothelin expressed by some adenocarcinomas. In this study, we evaluated MUC16 and mesothelin immunoreactivity by immunohistochemistry in 11 adenocarcinomas to the leptomeninges, 24 to mesothelin-negative brain, 8 metastases to mesothelin-expressing peritoneum/pleura, 22 to mesothelin-negative peripheral tissues, and 24 with no metastases. MUC16 was detected in 36% of leptomeningeal metastases and 10% of metastases to the brain. Adenocarcinoma metastases to mesothelin-expressing peritoneum or pleura exhibited extensive MUC16 in 75% of cases. In adenocarcinomas with local metastases to lymph nodes or no metastases, 53% or 38% had MUC16 immunoreactivity, respectively. Mesothelin-immunoreactivity was detected in 9% of metastases to the leptomeninges, 17% to the brain, none of the metastases to pleura/peritoneum, 50% of adenocarcinomas with local metastases to lymph nodes, etc, and 33% of adenocarcinomas without metastases. Mesothelin expression was significantly more common in nonmetastatic adenocarcinomas than in metastases to the pleura/peritoneum or leptomeninges. Our findings suggest that adenocarcinomas with MUC16 expression may have an increased risk for metastases to pleura/peritoneum but not the leptomeninges or brain.
Johnson
Mahlon D
MD
Department of Pathology, Division of Neuropathology, University of Rochester Medical Center, Rochester, NY 14623, USA. mahlon_johnson@urmc.rochester.edu
Vito
Fran
F
Xu
Haodong
H
Xu
Hoadong
H
D000230:Adenocarcinoma / Q000378:metabolism* / Q000556:secondary; D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D001932:Brain Neoplasms / Q000378:metabolism* / Q000556:secondary; D018394:CA-125 Antigen / Q000378:metabolism*; D058851:GPI-Linked Proteins; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D008562:Membrane Glycoproteins / Q000378:metabolism*; D008565:Membrane Proteins / Q000378:metabolism*; D008577:Meningeal Neoplasms / Q000378:metabolism* / Q000556:secondary; D000090204:Mesothelin; D009928:Organ Specificity; D010534:Peritoneal Neoplasms / Q000378:metabolism* / Q000556:secondary; D010997:Pleural Neoplasms / Q000378:metabolism* / Q000556:secondary; D012307:Risk Factors
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D058851:GPI-Linked Proteins; C451759:MUC16 protein, human; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D000090204:Mesothelin